Bioinformatical identification of key pathways and genes in human hepatocellular carcinoma after CSN5 depletion

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer.
• CSN5 depletion has shown prior efficacy in human HCC treatment.
• Identifying novel gene signatures and pathways is crucial for HCC therapeutic development.

Purpose of the Study:

• To identify key gene signatures and pathways involved in hepatocellular carcinoma (HCC).
• To elucidate the molecular mechanisms underlying CSN5 depletion's effect in HCC.
• To uncover potential therapeutic targets for HCC intervention.

Main Methods:

• Analysis of gene expression profiles from the GEO database (GSE26485).
• Differential gene expression analysis, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis.
• Protein-protein interaction (PPI) network construction, Kaplan-Meier survival analysis, western blot, immunohistochemistry, and ENCODE analysis.

Main Results:

• Identified 101 upregulated and 146 downregulated differentially expressed genes (DEGs) in HCC.
• DEGs were significantly enriched in pathways including cell growth regulation, oxidation-reduction, mitotic cytokinesis, and glutathione metabolism.
• CSN5 depletion inactivated H3K4me3 and H3K36me3 via downregulation of SMAD5-related pathways involving EXO1, CENPA, and NCAPG.

Conclusions:

• CSN5 depletion exerts therapeutic effects in HCC by targeting SMAD5-related pathways.
• Genes such as EXO1, CENPA, and NCAPG are critical mediators of CSN5's action in HCC.
• These findings highlight promising therapeutic targets for HCC patients.